Trastuzumab: beside an established treatment under test

192 studies: an approved drug, surgery or radiation is what the study tests. Page 2 of 2. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.

• A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With TrastuzumabActive, not recruitingNCT06681298Phase 2Report a problem
• Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2Report a problem
• A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast CancerStatus unknownNCT05871918Phase 3Report a problem
• Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)Active, not recruitingNCT05710666Phase 2Report a problem
• Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast CancerTerminatedNCT05553522Phase 1Report a problem
• Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2Report a problem
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2Report a problem
• Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2Report a problem
• Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Status unknownNCT04888663Phase 1/2Report a problem
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive, not recruitingNCT04873362Phase 3Report a problem
• Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast CancerWithdrawnNCT04856475Phase 2Report a problem
• Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2Report a problem
• Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast CancerActive, not recruitingNCT04759248Phase 2Report a problem
• Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast CancerStatus unknownNCT04665986Phase 3Report a problem
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2Report a problem
• Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast CancerWithdrawnNCT04419181Phase 2Report a problem
• A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04302441Phase 2Report a problem
• Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 PositiveActive, not recruitingNCT04249739Phase 2Report a problem
• Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationActive, not recruitingNCT04208178Phase 3Report a problem
• Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingNCT04193059Phase 3Report a problem
• ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCActive, not recruitingNCT04172259Phase 2Report a problem
• TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast CancerStatus unknownNCT04094896Phase 2Report a problem
• A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)CompletedNCT03988036Phase 2Report a problem
• Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer PatientsStatus unknownNCT03913234Phase 1/2Report a problem
• Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast CancerStatus unknownNCT03907800Phase 2Report a problem
• Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerTerminatedNCT03894007Phase 2Report a problem
• TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After SurgeryStatus unknownNCT03881878Phase 1/2Report a problem
• A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast CancerWithdrawnNCT03811418Phase 3Report a problem
• A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast CancerCompletedNCT03705429Phase 3Report a problem
• Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerActive, not recruitingNCT03595592Phase 3Report a problem
• Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast CancerActive, not recruitingNCT03571633Phase 2Report a problem
• Omission of Radiation in Patients With Her-2 Positive Breast CancerActive, not recruitingNCT03460067Not applicableReport a problem
• Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaCompletedNCT03409848Phase 2Report a problem
• Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic CancersWithdrawnNCT03323424Phase 2Report a problem
• Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsCompletedNCT03272477Phase 2Report a problem
• A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + TrastuzumabCompletedNCT03264547Phase 3Report a problem
• Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast CancerStatus unknownNCT03242551Phase 2Report a problem
• Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast CancerStatus unknownNCT03238495Phase 2Report a problem
• TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast CancerCompletedNCT03140553Phase 2Report a problem
• Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabCompletedNCT03135171Phase 1Report a problem
• Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast CancerActive, not recruitingNCT03125928Phase 2Report a problem
• Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast CancerWithdrawnNCT03058939Phase 2Report a problem
• Pembrolizumab, Trastuzumab, HER2 Positive Gastric CancerStatus unknownNCT02901301Phase 1/2Report a problem
• A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)CompletedNCT02738970Phase 1Report a problem
• Denosumab as an add-on Neoadjuvant Treatment (GeparX)CompletedNCT02682693Phase 2Report a problem
• Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and RadiotherapyActive, not recruitingNCT02679040Phase 2Report a problem
• Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionCompletedNCT02578368Phase 3Report a problem
• "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "CompletedNCT02530424Phase 2Report a problem
• A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast CancerCompletedNCT02514681Phase 3Report a problem
• A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCsStatus unknownNCT02510781Phase 2Report a problem
• Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2Report a problem
• Detect V / CHEVENDO (Chemo vs. Endo)Active, not recruitingNCT02344472Phase 3Report a problem
• Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A StatusCompletedNCT02339532Phase 2Report a problem
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialActive, not recruitingNCT02320435Phase 3Report a problem
• Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast CancerTerminatedNCT02229149Phase 2Report a problem
• Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast CancerCompletedNCT02199418Phase 2Report a problem
• Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal CarcinomatosisCompletedNCT02158988Phase 3Report a problem
• A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)CompletedNCT02125344Phase 3Report a problem
• Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast CancerStatus unknownNCT02041338Phase 2Report a problem
• Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2Active, not recruitingNCT01996267Phase 3Report a problem
• Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast CancerCompletedNCT01950182Phase 3Report a problem
• Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI ReconstructionStatus unknownNCT01917578Phase 3Report a problem
• Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast CancerStatus unknownNCT01880385Phase 1Report a problem
• IST Neoadjuvant Abraxane in Newly Diagnosed Breast CancerStatus unknownNCT01830244Phase 2Report a problem
• Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast CancerStatus unknownNCT01625429Phase 2Report a problem
• TraStuzumAb-Radiotherapy : Impact on the Cerebral PreventionTerminatedNCT01613482Phase 3Report a problem
• A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast CancerCompletedNCT01526369Phase 3Report a problem
• A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.CompletedNCT01485926Phase 2Report a problem
• ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast CancerCompletedNCT01472146Phase 2Report a problem
• Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsCompletedNCT01454804Phase 1Report a problem
• Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast CancerStatus unknownNCT01428414Phase 2Report a problem
• Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast CancerCompletedNCT01426880Phase 2/3Report a problem
• A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast CancerCompletedNCT01367028Phase 2Report a problem
• Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast CancerCompletedNCT01190345Phase 2Report a problem
• A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast CancerCompletedNCT01142778Phase 2Report a problem
• Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer AgentsCompletedNCT00790816Phase 1Report a problem
• Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy RegimensCompletedNCT00681993Not applicableReport a problem
• Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast CancerCompletedNCT00639366Phase 3Report a problem
• BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabTerminatedNCT00625898Phase 3Report a problem
• Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1Report a problem
• Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant ChemotherapyCompletedNCT00512993Phase 3Report a problem
• Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer PatientsTerminatedNCT00453635Phase 2Report a problem
• Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer PatientsTerminatedNCT00440622Phase 3Report a problem
• Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast CancerStatus unknownNCT00430001Phase 3Report a problem
• Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast CancerCompletedNCT00309556Phase 3Report a problem
• Trial of Myocet in Metastatic Breast CancerStatus unknownNCT00294996Phase 3Report a problem
• Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast CancerCompletedNCT00242203Phase 2Report a problem
• Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast CancerCompletedNCT00146549Phase 3Report a problem
• UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast CancerCompletedNCT00146042Phase 2Report a problem
• Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast CancerCompletedNCT00110695Phase 2Report a problem
• Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast CancerWithdrawnNCT00053339Phase 3Report a problem
• Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast CancerCompletedNCT00047255Phase 3Report a problem

← Trastuzumab